Ozoralizumab (ATN-103; 1 mg/kg; s.c.; Tg197 human TNF transgenic mice) inhibits arthritis and reduces arthritis scores[1].
| Animal Model: | Tg197 human TNF transgenic mice[1] |
| Dosage: | 1 mg/kg |
| Administration: | Subcutaneous injection |
| Result: | Reduced the mean histopathologic score in the Tg197 mice.
Had ability to neutralize TNFα activity.
|
